Editor-in-chief
Maria Stella Graziani

Deputy Director
Martina Zaninotto

Associate Editors
Ferruccio Ceriotti
Davide Giavarina
Bruna Lo Sasso
Giampaolo Merlini
Martina Montagnana
Andrea Mosca
Paola Pezzati
Rossella Tomaiuolo
Matteo Vidali

International Advisory Board Khosrow Adeli Canada
Sergio Bernardini Italy
Marcello Ciaccio Italy
Eleftherios Diamandis Canada
Philippe Gillery France
Kjell Grankvist Sweden
Hans Jacobs The Netherlands
Eric Kilpatrick UK
Magdalena Krintus Poland
Giuseppe Lippi Italy
☩Howard Morris Australia
Mario Plebani Italy
Sverre Sandberg Norway
Ana-Maria Simundic Croatia
☩Jill Tate Australia
Tommaso Trenti Italy
Cas Weykamp The Netherlands
Maria Willrich USA
Paul Yip Canada


Publisher
Biomedia srl
Via L. Temolo 4, 20126 Milano

Responsible Editor
Giuseppe Agosta

Editorial Secretary
Arianna Lucini Paioni
Biomedia srl
Via L. Temolo 4, 20126 Milano
Tel. 0245498282
email: biochimica.clinica@sibioc.it



Area soci
Non possiedi o non ricordi la password!
Clicca qui

BC: Articoli scritti da C. Cocco

Il ruolo di CA 15-3 nel monitoraggio della terapia nel carcinoma mammario metastatico
Role of CA15-3 to guide therapy in metastatic breast cancer
C. Cocco  |  B. Caruso  |  E. Fiorio  | 
<p>The National Academy of Clinical Biochemistry&nbsp;states that cancer antigen 15-3 (CA15-3) in combination with imaging and clinical examinations can be used for&nbsp;therapeutic monitoring in patients with advanced breast cancer. In a 62 year old patient with a 2 year history of&nbsp;invasive ductal breast carcinoma and bone metastasis, treated with an aromatase inhibitor, the imaging showed bone&nbsp;marrow infiltration and liver metastasis. The oncologist planned a close monitoring of the disease and the patient has&nbsp;been followed for two years by CA15-3 every month and imaging when necessary. It has been observed that the&nbsp;clinician modified the therapy on the basis of the CA15-3 values during two phases of apparent stability of the&nbsp;disease. This case report shows that the CA15-3 has contributed to a large extent to stop ineffective treatments and&nbsp;has effectively helped the clinician in selecting the most appropriate treatment options. However, it is to be noted that&nbsp;the monthly request of the marker is not appropriate.</p>
Biochimica Clinica ; 40(2) e08-e11
Casi clinici - Case report
 
Le analisi immunometriche: basi teoriche e applicazioni cliniche
C. Cocco  | 
Biochimica Clinica ; 38(4) 350-351
Recensioni - Book reviews
 
Procalcitonina e sepsi: alcuni aspetti relativi all’appropriatezza della richiesta
Procalcitonin and sepsis: hints on clinical appropriateness
<p>Sepsis in know to be a challenge for clinicians, given the poor outcome and high costs. Both diagnosis and management are a matter of concern, as appropriate and early therapy can result in higher survival rate. Various biological parameters have been proposed to establish diagnosis<br />and evaluate risk. Procalcitonin (PCT), the precursor of calcitonin, has gained attention as serological marker of sepsis and several authors have claimed for PCT a role in rapid diagnosis as well as risk stratification and prognosis evaluation. Data from systematic reviews support the use of PCT as an alternative to C-reactive protein in adult intensive care unit patients, although its use as sole diagnostic marker does not appear to be appropriate in critical patients. In the emergency department setting PCT can be used to rule out sepsis in adult febrile patients. Data on risk stratification and prognosis are less clear cut and specific clinical questions need further investigation.</p>
Biochimica Clinica ; 37(1) 15-22
Rassegne - Reviews
 
E' possibile utilizzare la determinazione della lipocalina associata alla gelatinasi dei neutrofili (NGAL) nella valutazione della nefrotossicità da bisfosfonati?
IS THERE A ROLE FOR NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (NGAL) IN DETECTION OF BIPHOSPHONATE NEPHROTOXICITY?
Biochimica Clinica ; 35(4) 331
LETTERE ALL'EDITORE - LETTERE ALL'EDITORE